Multiantigen IgG+IgA+IgM is a multiplex, microsphere-based, highly sensitive and specific assay that measure the presence or absence of antibodies against four different SARS-CoV-2 antigens simultaneously.
Detecting SARS-CoV-2 neutralizing antibodies.
Identifying immune response after vaccination.
Identifying immune response to natural infection.
Identifying immune response to viral replication.
This serological bead-based assay has demonstrated to provide a wider range of information about the immune system response to SARS-CoV-2 than any other assay in the market, and it is performed in just 2 hours.
12×8 well (12X8) black microtiter with lid. For protocol with plate.
Magnetic polystyrene microspheres with a diameter (µm) 5.5 ±0.2 (CV<5%), coated with the following SARS-CoV-2 antigens:
40 ml wash buffer (10X). PBS 10% BSA, pH 7.4 – 10X. Contains 10% albumin in 10mM sodium phosphate, 150mM NaCl, pH 7.4, contains KATHON™ anti-microbial agent.
10 ml of sample diluent buffer (1X – Ready to use).
Buffer that minimises non-specific binding, cross-reactivity and matrix interference, with blue dye. Contains CMIT/MIT 3:1 as preservative.
Immunogenicity results are reported as an international standard unit. IU/mL for neutralising antibodies (RBD) and BAU/mL for S, N and Mpro Proteins.
Single Receptor-binding domain of S-glycoprotein (RBD) coated beads.
Single stable trimer of the spicule glycoprotein (S) coated beads
Single Nucleocapsid protein (N) coated beads
Single Main virus protease or 3C-typeprotese (3CLpro,Mpro) coated beads.
Contains < 0.0014 % [w/w] reaction mass of CMIT/MIT (3:1).
Contains 10 % albumin in 10mM sodium phosphate, 150 mM NaCl, pH 7.4, contains KATHON anti-microbial agent.
Different serology tests detect antibodies to different parts of the virus. After vaccination, the antibodies will only be formed to one part of the virus (the Spike protein). To detect if vaccination stimulated an antibody response, a test specifically designed for the antibodies of interest is needed.
This test presents a great opportunity because it gives so much information about the immune response based on the detection of 3 types of immunoglobulins and 4 specific SARS-CoV-2 antigens simultaneously, allowing us to differentiate the immune response for clinical infection and vaccination.
If you fill the form above indicating your interested kit, one of our specialists will contact you with the exact details.
You can also write at firstname.lastname@example.org with the corresponding reference number you can see in the table.
Or you can contact us by phone at+34 923 29 48 27 (Spain).
CE/IVD kits are only suitable for clinical use in European Union and countries with EU conformity recognition agreements. Manufactured in Spain by Immunostep under CSIC Patent Licence.
The SARS-CoV-2 Multiplex assay has been calibrated against the WHO First International Standard for Anti-SARS-CoV-2 Immunoglobulin (Human), NIBSC Code 20/136.
In this sense, it is possible to quantitatively report the concentration of IgG immunoglobulins in International Units (IU / ml) against RBD or in United Antibody Units (BAU / ml) against S, N and Mpro. For this reason, the kit includes a calibrator or standard of known concentration with which to make a calibration line through serial dilutions to each of the viral antigens used in the test (RBD, S, N, Mpro) in which to interpolate the fluorescence values resulting from the assay of the samples, thus obtaining the concentration in IU / ml or BAU / ml corresponding to each sample.
These tests are for professional use only. If you are interested in acquiring these kits, please, contact us by email at email@example.com, and we will contact you shortly.
If you are a particular and you want to acquire this test, please contact us in order to recieve a personalized proposal of our partners near you.
Our products are available through our extensive distribution network all over the world. Please contact us and we will give you all the information shortly.
Project subsidized by the Ministry of Industry, Trade and Tourism, as part of the aid program for the manufacture of health material for the COVID-19 crisis (2020) with the objective of creating a production line of SARS-CoV-2 Multi-antigen serological tests for Flow Cytometry.